About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Antonio | 12,572 Studies Near You | Clareo Health

Clinical Trials LocationsSan Antonio

Clinical Trials in San Antonio

Discover 12,572 clinical trials near San Antonio, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3021-3040 of 12,572 trials

Active Not RecruitingPhase 1< 1 mile

QTX3046 in Patients With KRAS G12D Mutations

NCT06428500

Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.

Advanced Solid Tumor

Quanta Therapeutics240 participantsStarted May 2024

Grand Rapids, Michigan, United States • Durham, North Carolina, United States • Houston, Texas, United States +2 more locations

COMPLETEDPhase 3< 1 mile

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

NCT04028492

To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.

Idiopathic GastroparesisDiabetic GastroparesisGastroparesis

Vanda Pharmaceuticals992 participantsStarted Aug 2019

Birmingham, Alabama, United States • Peoria, Arizona, United States • Little Rock, Arkansas, United States +33 more locations

Find Trials by Condition in San Antonio

Breast Cancerin San Antonio Lung Cancerin San Antonio Prostate Cancerin San Antonio Colorectal Cancerin San Antonio Melanomain San Antonio Leukemiain San Antonio Lymphomain San Antonio Pancreatic Cancerin San Antonio Ovarian Cancerin San Antonio Brain Cancerin San Antonio

Data from ClinicalTrials.govTerms

RECRUITINGPhase 2< 1 mile

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493

This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.

Persistent Corneal Epithelial Defect

Glaukos Corporation84 participantsStarted Aug 2023

Dothan, Alabama, United States • Petaluma, California, United States • Torrance, California, United States +25 more locations

RECRUITING< 1 mile

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

NCT00736749

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

Hematopoietic Cell Transplantation RecipientLeukemiaSolid Tumor

Children's Oncology Group5,000 participantsStarted Jul 2008

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Mobile, Alabama, United States +161 more locations

TERMINATEDPhase 3< 1 mile

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

NCT03744910

This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.

Antibody-mediated Rejection

CSL Behring194 participantsStarted Oct 2019

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +139 more locations

COMPLETEDPhase 2< 1 mile

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116

The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.

Nonalcoholic Steatohepatitis (NASH)

NGM Biopharmaceuticals, Inc254 participantsStarted Jul 2015

Chandler, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +19 more locations

Active Not RecruitingPhase 3< 1 mile

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

NCT05882045

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

ObesityCardiovascular Diseases

Eli Lilly and Company1,800 participantsStarted May 2023

Phoenix, Arizona, United States • Covina, California, United States • Fresno, California, United States +166 more locations

COMPLETEDPhase 374 miles

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

NCT03607838

This study is to evaluate the effectiveness of a single-dose intervertebral disc injection of SI-6603 in subjects with lumbar disc herniation (LDH)

Lumbar Disc Herniation

Seikagaku Corporation352 participantsStarted Nov 2018

Mobile, Alabama, United States • Fountain Valley, California, United States • La Jolla, California, United States +64 more locations

COMPLETEDPhase 374 miles

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

NCT04026412

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb925 participantsStarted Oct 2019

La Jolla, California, United States • San Francisco, California, United States • San Francisco, California, United States +180 more locations

COMPLETEDPhase 374 miles

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

NCT05360966

This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit) for an individual duration of participation of approximately 15 weeks.

Dry Eye Disease

Aerie Pharmaceuticals467 participantsStarted Jul 2022

Chico, California, United States • Fullerton, California, United States • Newport Beach, California, United States +20 more locations

TERMINATEDPhase 2172 miles

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

NCT04864392

The study will determine the optimal dosing regimen of LNA043 in patients with knee osteoarthritis (OA).

Novartis Pharmaceuticals582 participantsStarted May 2021

Phoenix, Arizona, United States • Tucson, Arizona, United States • La Mesa, California, United States +73 more locations

TERMINATEDPhase 2190 miles

Open-Label Surufatinib in European Patients With NET

NCT04579679

This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).

Neuroendocrine TumoursNeuroendocrine Tumour of the LungSmall Intestinal NET

Hutchmed78 participantsStarted Aug 2021

Birmingham, Alabama, United States • Orange, California, United States • Atlanta, Georgia, United States +20 more locations

COMPLETEDNA190 miles

This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.

NCT06666426

This post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their quality of life before and after using the device.

Adult Nocturnal EnuresisUrinary Incontinence (UI)

C. R. Bard171 participantsStarted Oct 2024

Guntersville, Alabama, United States • Chandler, Arizona, United States • Eagle Rock, California, United States +12 more locations

COMPLETEDPhase 3190 miles

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

NCT03823287

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

Wet Macular Degeneration

Hoffmann-La Roche671 participantsStarted Feb 2019

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +158 more locations

COMPLETEDNA190 miles

Wavefront-guided LASIK for Monovision Treatment of Myopic Subjects With Presbyopia

NCT04075591

This study will be a 12-month, prospective, multicenter, open-label, non-comparative, non-randomized clinical investigation conducted at 8 to 14 sites. A total of 383 subjects will be enrolled to achieve approximately 268 treated subjects, resulting in at least 241 evaluable subjects at the point of refractive stability. After signing the informed consent, subjects meeting all inclusion and exclusion criteria in both eyes may be scheduled for surgery. The follow-up visit schedule will be the same for each operative eye.

Refractive Error

AMO Development, LLC219 participantsStarted Sep 2019

Los Angeles, California, United States • Chicago, Illinois, United States • Las Vegas, Nevada, United States +7 more locations

RECRUITING793 miles

Ceribell Delirium Data Collection Study

NCT04962815

This study is designed as a prospective, non-randomized, observational clinical study. The study will collect clinical and rrEEG (Ceribell EEG) data when monitoring subjects for delirium subtypes. EEG and clinical data will be collected for the development of future software algorithms to assess the presence and severity of delirium.

Ceribell Inc.200 participantsStarted Nov 2021

Stanford, California, United States • Naples, Florida, United States • Iowa City, Iowa, United States +4 more locations

COMPLETEDPhase 2798 miles

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

NCT04924101

The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.

Small Cell Lung Cancer

Merck Sharp & Dohme LLC126 participantsStarted Jul 2021

Gilbert, Arizona, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +46 more locations

COMPLETEDPhase 1823 miles

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05177042

Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA values on abiraterone.

Prostate Cancer Metastatic

Arvinas Androgen Receptor, Inc.45 participantsStarted Feb 2022

Santa Monica, California, United States • New Haven, Connecticut, United States • Fort Myers, Florida, United States +15 more locations

COMPLETEDPhase 1823 miles

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

NCT04257110

This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of BB-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, gastric/gastroesophageal junction cancer, bladder cancer and colon cancer, for exploring 1 or more RP2Ds or schedules for expanding/deepening the information/knowledge about clinical safety, clinical pharmacokinetics and anti-tumor activity.

Locally Advanced/Metastatic HER2 Positive Solid Tumors

Bliss Biopharmaceutical (Hangzhou) Co., Ltd117 participantsStarted Jul 2020

San Francisco, California, United States • Nashville, Tennessee, United States • Fairfax, Virginia, United States +9 more locations

RECRUITINGNA977 miles

Non-surgical Spinal Decompression Therapy and Outcomes

NCT06525896

This project will determine the clinical utility of non-surgical spine decompression for chronic low back pain (LBP). LBP is one of the highest incidence medical conditions that contributes to disability, decreased activities of daily living, decreased quality of life, and inability to work. LBP affects ≈70-85% of people during their lifetime, with ≈20% becoming chronic by age 20-59 years. Many current LBP therapeutics have detrimental long-term effects, undesired side effects, are invasive procedures with low success rates, and do not fare better than conservative care. Further, many chronic musculoskeletal pain patients do not respond to surgery, and many develop dependence on opioids. This project will implement a small-scale double-blinded, randomized proof-of-concept clinical trial to gather biomechanical and MRI data that will objectively determine the effectiveness of non-surgical spinal decompression (NSSD) over a 12-week longitudinal timeframe. The potential to provide a non-invasive alternative to chronic LBP via NSSD is innovative and addresses the pressing need for safer, more effective pain management options with fewer negative sequelae. NSSD has the potential to greatly improve lives, offering a new paradigm for chronic pain management.

Low Back PainHerniation, DiscSciatic Radiculopathy+2 more

University of South Florida42 participantsStarted Jan 2025

Stanford, California, United States • Tampa, Florida, United States

PreviousPage 152 of 629Next

Diabetes

in San Antonio

Heart Diseasein San Antonio